+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Adjuvant chemotherapy beneficial for select early-stage, low-grade serous ovarian cancer patients

Adjuvant chemotherapy beneficial for select early-stage, low-grade serous ovarian cancer patients

Gynecologic Oncology 141: 187-188

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 064806181

Download citation: RISBibTeXText

DOI: 10.1016/j.ygyno.2016.04.484

Related references

The effect of adjuvant chemotherapy on survival in patients with FIGO stage I high-grade serous ovarian cancer. Gynecologic Oncology 2019, 2019

Role of adjuvant chemotherapy in patients with early stage uterine papillary serous cancer. International Journal of Gynecological Cancer 21(8): 1436-1440, 2012

Impact of adjuvant chemotherapy and surgical staging in early-stage ovarian carcinoma: European organisation for research and treatment of cancer-adjuvant chemotherapy in ovarian neoplasm trial. Journal of the National Cancer Institute 95(2): 113-125, January 15, 2003

BRAF mutation is associated with early stage disease and improved outcome in patients with low-grade serous ovarian cancer. Cancer 119(3): 548-554, 2013

HOXA4/HOXB3 gene expression signature as a biomarker of recurrence in patients with high-grade serous ovarian cancer following primary cytoreductive surgery and first-line adjuvant chemotherapy. Gynecologic Oncology 149(1): 155-162, 2018

The role of adjuvant chemotherapy as a prognostic factor in patients with early stage of epithelian ovarian cancer (I - II stage). Akusherstvo i Ginekologiia 52(1): 58-61, 2013

Response: Re: Adjuvant Chemotherapy in Patients With Early-Stage Ovarian Cancer. Jnci Journal of the National Cancer Institute 95(15): 1170-1171, 2003

Clinical Practice of Adjuvant Chemotherapy in Patients with Early-Stage Epithelial Ovarian Cancer. ChemoTherapy 61(6): 287-294, 2017

International Collaborative Ovarian Neoplasm trial 1 and Adjuvant ChemoTherapy In Ovarian Neoplasm trial: Two parallel randomized phase III trials of adjuvant chemotherapy in patients with early-stage ovarian carcinoma. Journal of the National Cancer Institute 95(2): 105-112, January 15, 2003

The number of cycles of neoadjuvant chemotherapy is associated with prognosis of stage IIIc-IV high-grade serous ovarian cancer. Archives of Gynecology and Obstetrics 295(2): 451-458, 2016

Surgical Stage I high-grade ovarian cancer: is adjuvant chemotherapy warranted?. European Journal of Gynaecological Oncology 36(6): 633-636, 2016

No survival benefit with adjuvant chemotherapy in nonserous stage IB grade 2 epithelial ovarian cancer. Gynecologic Oncology 141: 53-54, 2016

Ascites regression following neoadjuvant chemotherapy in prediction of treatment outcome among stage IIIc to IV high-grade serous ovarian cancer. Journal of Ovarian Research 9(1): 85, 2017

Outcomes of Non-High Grade Serous Carcinoma after Neoadjuvant Chemotherapy for Advanced-Stage Ovarian Cancer: Single-Institution Experience. Yonsei Medical Journal 59(8): 930-936, 2018

Autoantibodies against HSF1 and CCDC155 as Biomarkers of Early-Stage, High-Grade Serous Ovarian Cancer. Cancer Epidemiology, Biomarkers and Prevention 27(2): 183-192, 2017